EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Real-World Multicentre Evaluation of GALEAS Bladder for Detecting Bladder Cancer in UK NHS Haematuria Clinics

Lee Silcock, Robert K Hastings, Samuel Clokie, Rebecca Sadler, Michael Parks, Matthew Smith, Victoria Hewitt, Jayne Louise Douglas-Moore, Helena Wignall, Hugo Escabelado, John Piedad, Sagar Kanabar und 13 weitere

European Urology Oncology · 2026-10 · 9 (5) · 1155-1161

DOI: 10.1016/j.euo.2026.08.005 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Urology Oncology, 2026-10. Verfasst von Lee Silcock und 24 weiteren Autor:innen. Beteiligte Einrichtung: Nonacus Ltd, Birmingham, UK. Hauptthemen laut MEDLINE: Hematuria, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Cystoscopy is a core component of haematuria investigations; however, it is invasive and resource intensive. GALEAS Bladder is a DNA-based diagnostic urine test that measures mutations in 23 bladder cancer (BC)-associated genes. OBJECTIVE: We aimed to assess the diagnostic performance of GALEAS Bladder in real-world patients with haematuria and its utility as a molecular triage tool in this setting. METHODS: Patients referred for urgent investigation of haematuria were prospectively enrolled across seven UK National Health Service urology departments between October 2024 and June 2025. Urine samples were collected prior to cystoscopy and analysed by GALEAS Bladder. Assay results were compared with cystoscopy and biopsy/transurethral resection of bladder tumour findings. KEY FINDINGS AND LIMITATIONS: Cystoscopic findings and GALEAS Bladder results were available for 964 participants (575 visible and 294 non-visible haematuria, 95 unknown), including 77 (8.0%) newly diagnosed with pathology-confirmed BC. The assay detected 71 of the 77 BCs, including all 17 muscle-invasive BCs and 35 of the 36 high-grade BCs, with negative predictive value >99% (95% confidence interval [CI] 98-100), positive predictive value 50% (95% CI 42-58), positive likelihood ratio (LR) 11.5, and negative LR 0.09. Decision curve analysis showed net benefit over cystoscopy for all referrals. Limitations include observational study design over a limited timeframe and absence of subsequent diagnoses for participants with positive GALEAS Bladder test results without cystoscopically visible tumour. CONCLUSIONS AND CLINICAL IMPLICATIONS: GALEAS Bladder is a clinically implementable molecular urine test that detects new cases of BC with high negative predictive value and favourable LRs in patients undergoing urgent investigation of haematuria. These data show that GALEAS Bladder can be used now to triage patients with haematuria to immediate or deferred cystoscopy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HematuriaUrinary Bladder NeoplasmsHumansFemaleMaleUnited KingdomAgedCystoscopyProspective StudiesMiddle AgedNon-Muscle Invasive Bladder Neoplasms

Stichwörter der Autor:innen

Bladder cancerDNADiagnosisGALEAS BladderNoninvasiveSNVUrine

Autor:innen und Institutionen

  • Nonacus Ltd, Birmingham, UK.
  • University Hospitals of Leicester NHS Trust, Leicester, UK.
  • Department of Urology, Royal Berkshire Hospital, Reading, UK.
  • Department of Urology, Manchester University NHS Foundation Trust, Manchester, UK.
  • Kingston and Richmond NHS Foundation Trust, Kingston upon Thames, UK.
  • Dorset County Hospital NHS Foundation Trust, Dorchester, UK.

Zitieren

APA

Silcock, L., Hastings, R. K., Clokie, S., Sadler, R., Parks, M., Smith, M., Hewitt, V., Douglas-Moore, J. L., Wignall, H., Escabelado, H., Piedad, J., Kanabar, S., Blick, C., Mohee, A., Pumfrey, N., Coull, N., Goffe, A., Tippett, R., Laird, A., …, & Bryan, R. T. (2026). Real-World Multicentre Evaluation of GALEAS Bladder for Detecting Bladder Cancer in UK NHS Haematuria Clinics. European Urology Oncology, 9(5), 1155-1161. https://doi.org/10.1016/j.euo.2026.08.005

Vancouver

Silcock L, Hastings RK, Clokie S, Sadler R, Parks M, Smith M, et al. Real-World Multicentre Evaluation of GALEAS Bladder for Detecting Bladder Cancer in UK NHS Haematuria Clinics. European Urology Oncology. 2026;9(5):1155-1161. doi:10.1016/j.euo.2026.08.005

BibTeX
@article{Silcock2026,
  author = {Silcock, Lee and Hastings, Robert K and Clokie, Samuel and Sadler, Rebecca and Parks, Michael and Smith, Matthew and Hewitt, Victoria and Douglas-Moore, Jayne Louise and Wignall, Helena and Escabelado, Hugo and Piedad, John and Kanabar, Sagar and Blick, Chris and Mohee, Amar and Pumfrey, Niall and Coull, Nadine and Goffe, Andy and Tippett, Richard and Laird, Alexander and Shah, Chandrarajan Premal and MacKay, Murray and Owen, Catherine and Mufti, Uwais and Ward, Douglas G and Bryan, Richard T},
  title = {Real-World Multicentre Evaluation of GALEAS Bladder for Detecting Bladder Cancer in UK NHS Haematuria Clinics},
  journal = {European Urology Oncology},
  year = {2026},
  volume = {9},
  number = {5},
  pages = {1155--1161},
  doi = {10.1016/j.euo.2026.08.005}
}
Kostenlos starten →